Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 16/20 | 0.44 |
| ▸ | CNR1 | P21554 | 9/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4091337 | 0.84 | CNR2 (0.49) | CNR2CNR1 | |
| SCHEMBL4090263 | 0.83 | CNR2 (0.60) | CNR2CNR1ADORA1 | |
| SCHEMBL4090931 | 0.79 | CNR2 (0.45) | CNR2CNR1ADORA1P2RX7 | |
| SCHEMBL3799426 | 0.75 | CNR2 (0.40) | CNR2CNR1ADORA1P2RX7 | |
| SCHEMBL4086759 | 0.75 | CNR2 (0.40) | CNR2CNR1ADORA1P2RX7 | |
| SCHEMBL927467 | 0.74 | CNR2 (0.45) | CNR2CNR1ADORA1P2RX7 | |
| SCHEMBL3640627 | 0.74 | CNR2 (0.70) | CNR2CNR1 | |
| SCHEMBL4091403 | 0.73 | CNR2 (0.69) | CNR2CNR1 | |
| SCHEMBL4086532 | 0.73 | CNR2 (0.69) | CNR2CNR1 | |
| SCHEMBL21261183 | 0.73 | FABP4 (0.38) | FABP4FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338623-B2 | N-{3-[(2,5-dimethylmorpholin-4-yl)carbonyl]-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl}hexahydro-2,5-methanopentalene-3a(1H)-carboxamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBVIE INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20090018114-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018114-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885ADORA1 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.